Top Markets
Coin of the day
Acura Pharmaceuticals, Inc. Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc.

ACUR
Rang in Aktien #41978
Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to... Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to exploring, developing, and bringing to market novel technologies and products aimed at enhancing medication safety across the United States. Its product portfolio features Oxaydo tablets, a potent Schedule II narcotic prescribed for managing both acute and chronic moderate-to-severe pain. The company also offers the Nexafed line, consisting of pseudoephedrine and acetaminophen tablets, widely utilized as nasal decongestants in a range of over-the-counter and prescription formulations for cold, sinus, and allergy relief. Beyond its current offerings, Acura is actively advancing six additional opioid products through various stages of formulation development. To support its global reach, Acura Pharmaceuticals maintains strategic collaboration and licensing agreements with Egalet US, Inc. and Egalet Ltd. for the worldwide production and commercialization of its Oxaydo products. Furthermore, it has established a development and commercialization partnership with Abuse Deterrent Pharma, LLC to create LTX-03, an immediate-release tablet leveraging the proprietary LIMITx technology. Established in 1935, the company's operations are headquartered in Palatine, Illinois.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$6.60K
Veränderung (1 Tag)
-50.00%
Veränderung (1 Jahr)
-80.00%
Land
US
Handel Acura Pharmaceuticals, Inc. (ACUR)

Kategorie

EPS für Acura Pharmaceuticals, Inc. (ACUR)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Acura Pharmaceuticals, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Acura Pharmaceuticals, Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber